Bubble Intelligence

Market Intelligence For The New Regime

VERTEX PHARMACEUTICALS INC / MA
VRTX
Latest Filing: May 5, 2026 • 25 Total Filings
Total Assets
2026
$26.48B
Total Revenue
2026
$2.99B
Net Income
2026
$1.03B
Operating Cash Flow
2026
$1.43B
Filing Year:
2024
Only 2024 data available
Data Source:
Showing data from all document types
Filters:
located incompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes with
VERTEX PHARMACEUTICALS INC / MA
Ticker: VRTX
Unknown Region
1 supplier
Lonza
contract_manufacturer
Takeda
AbbVie Inc.
Eli Lilly and Company
Oncology (Vectibix vs ERBITUX)
Major Competitor
AstraZeneca
Collaboration partner, not a competitor in this context
Merck
Novo Nordisk A/S
Novartis
Competition for marketed products
Roche
Libtayo competes with Tecentriq
Major Competitor
Sionna Therapeutics, Inc.
Cystic fibrosis therapeutics
Arcturus Therapeutics Holdings, Inc.
Cystic fibrosis nucleic acid therapies
ReCode Therapeutics, Inc.
Cystic fibrosis nucleic acid therapies
Krystal Biotech, Inc.
Cystic fibrosis nucleic acid therapies
Spirovant Sciences, Inc.
Cystic fibrosis nucleic acid therapies
Boehringer Ingelheim International, GmbH
Cystic fibrosis nucleic acid therapies
4D Molecular Therapeutics, Inc
Cystic fibrosis nucleic acid therapies
SpliSense, Ltd.
Cystic fibrosis nucleic acid therapies
Novartis International AG
Sickle cell disease and beta thalassemia
Bristol Myers Squibb
Sickle cell disease and beta thalassemia
Merck & Co.
Sickle cell disease and beta thalassemia
bluebird bio, Inc.
Sickle cell disease and beta thalassemia
Pfizer Inc.
Sickle cell disease
Beam Therapeutics
Sickle cell disease
Agios Pharmaceuticals
Sickle cell disease and beta thalassemia
Latigo Bio
Pain therapeutics
SiteOne Therapeutics
Pain therapeutics
Lexicon Pharmaceuticals Inc.
Pain therapeutics
Sernova Corp
T1D
Sana Biotechnology, Inc.
T1D
Seraxis, Inc.
T1D
Evotec A.G.
T1D
Maze Therapeutics
AMKD
OmniAb
AMKD
Calliditas
IgAN
Travere Therapeutics
IgAN
Otsuka Pharmaceutical Co., Ltd
IgAN
Vera Therapeutics
IgAN
RemeGen
IgAN
Ionis Pharmaceuticals
IgAN
Biogen
IgAN
Fair Therapeutics
Cystic Fibrosis
bluebird
Competition for CASGEVY in SCD and TDT
Major Competitor
React Flow
Legend:
Company
Critical Supplier
Significant Supplier
Standard Supplier
Major Competitor
Emerging Competitor
Competitor
Regional Supplier Concentration
0 regions with known supplier geography · 1 supplier without location data
Risk:LowModerateElevatedHigh
1 supplier · no geography